Congress Approves Continuing Resolution Through December 11

As Congress was not able to come to an agreement on the appropriations bills to fund the federal government for the next fiscal year (FY) in advance of the September 31 deadline, policy makers instead passed a Continuing Resolution that essentially funds the government at the prior year levels through December 11 2020.

While it was important to avoid a shutdown in the midst of a pandemic, the Endocrine Society and other biomedical research advocates are disappointed that Congress was unable to agree on a full-year appropriations package with robust funding for the National Institutes of Health and emergency supplemental funds to help federal researchers recover and continue important work on national health priorities.

Moving the deadline for FY2021 funding past the election gives lawmakers more flexibility, but it means that we and others will need to keep up pressure over these important weeks to ensure that Congress completes their job and delivers a full-year package that funds the NIH and other research funding agencies at appropriate levels. Please visit the Endocrine Society’s advocacy webpage at for details on how you can add your voice and join our campaign

You may also like

  • Endocrine Society Participates in European Union Activity to Advise on Implementation of its Chemical Strategy

    The Endocrine Society achieved a major victory in the new European Union (EU) Chemicals Strategy for Sustainability (CSS) by including several priority actions on endocrine-disrupting chemicals (EDCs) within the strategy. The CSS commits the EU towards a series of actions to better protect citizens and the environment and promote innovation in safe and sustainable chemicals….

  • Endocrine Society Leads Efforts to Lower Cost of Prescription Drugs

    The Endocrine Society continues to lead advocacy efforts focused on lowering the cost of diabetes medication. The Society has weighed in on recent congressional and administration activity regarding legislation and regulations aimed at lowering the price of prescription drugs.    In May, the House Energy & Commerce Health subcommittee conducted a hearing on legislation to lower the cost of prescription drugs. The Endocrine Society submitted a statement to the subcommittee calling on Congress to…

Find more in